Skip to main content

CAR T-Cell Therapy - Treatment of Various Hematological Malignancies

 

CAR T-cell (Chimeric Antigen Receptor T-cell) therapy is used predominantly in the treatment of various hematological malignancies (HMs), such as acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), lymphoma (diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma), and multiple myeloma (MM). HMs are blood cancers caused due to the uncontrolled growth of lymphoid and hematopoietic tissues (bone marrow). HMs are clinically and biologically heterogeneous disorders responsible for nearly 6.5% of all cancers across the globe, around 9.0% of cancers in the U.S. and Europe collectively. According to the estimates provided by Global Cancer Observatory (Globocan), an international agency for research on cancer, the total number of prevalent cases of hematologic malignancies in the world was 2,903,711 in 2018. The U.S. contributed around 15% of global prevalent cases of hematologic malignancies, and China contributed around 17% of total cases in 2018. As per the data published by the Leukemia and Lymphoma Society, in the U.S., approximately one person is diagnosed with hematologic cancer every three minutes. It is also estimated that by the end of 2020, the incidence of leukemia, lymphoma, or myeloma in the U.S. will reach 178,520 cases.

View BIS Report CAR T-Cell Therapy Market

About BIS Research

BIS Research, a premium market intelligence company offers in-depth insights and consulting to Fortune 500 companies. We are established and known for tracking the growth of deep technologies across key industry verticals and the subsequent challenges and opportunities associated with deep tech across markets, applications and products.

 

With more than 500 clients, over 7000 plus primary interviews and approximately 200 reports published in a year BIS Research has set an interesting growth trajectory for itself. We provide market estimations, emerging high-growth applications, technology analysis, highly segmented granular country-level market data, and other important market parameters that come in handy for our clients during strategic decision-making.

We publish a wide gamut of syndicated market studies across industry verticals. In addition, bespoke market studies is another area where BIS Research excels at along with consulting services.

Labels:

Comments

Post a Comment

Popular posts from this blog

Understanding How the Human Centric Lighting Market is Segmented

Lighting plays a significant role in the lives of people, it has the potential to bring about positive changes in people’s behaviour. In the year 1989, a research was carried out and it proved that natural daylight can trigger the production of melatonin and serotonin, two of the most important hormones in the human body. These two hormones are responsible for inducing peaceful sleep and happiness in people. This led to the research and development in the field of human centric lighting (HCL). According to a report published by the BIS Research , the HCL market is expected to grow at a CAGR of 37.2% and 35.2% both in terms of volume and value during the forecast period (2018 – 2024). The HCL is segmented by the component, end-user and by region. Request the Sample: Human Centric Lighting Market The human centric lighting market can be further segmented by component, type, end-users, and region. The components or the controls are further segmented as microprocessors & microco...
Post a Comment
Read more

Liquid Biopsy, North America, and Lung Cancer Occupying a Major Share in the Market

  Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market . However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030. Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chron...
Post a Comment
Read more

Global Surgical Robotics Market: Analysis and Forecast, 2018-2025

Global Surgical Robotics Market: Focus on Products and Services (Surgical Systems, Instruments & Accessories, and Services & Maintenance), Applications, End Users, and Competitive Landscape: Analysis and Forecast, 2018-2025. Rising incidences of colorectal cancer, neurological disorders, interventional cardiology disorders and gynecological diseases, growing geriatric population, and active participation of the government and the industry players in the technological advancement in the field of computer assisted robotic surgeries have boosted the overall growth of this market. Another factor which significantly contributes to the revenue generation of a company is the recurring sale of equipment and accessories of a surgical system. The surgical robotics vendors generate revenue through one time sale of the surgical system and generate the recurring  revenue from the sale of equipment and accessory products and maintenance services used in the surgical system. A...
1 comment
Read more